Pfizer seeks approval for new Viagra use

Share this article:
Pfizer has filed applications with the FDA and European regulators for approval of its male impotence drug Viagra to treat the potentially fatal lung disorder pulmonary arterial hypertension.
The drug would be called Revatio for the new indication, not Viagra, and would be manufactured and marketed in a different dosage, color and shape than Viagra, the New York-based drug maker said.
Pulmonary arterial hypertension treatments include calcium channel blocker drugs Norvasc and Procardia XL, also manufactured by Pfizer and Biovail's Cardizem.
An approval would add to worldwide sales of Viagra, which generated $1.9 billion in revenue for 2003, according to a Bloomberg News report.
Share this article:

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.